Through our unique approach to gene science based on Nobel Prize-winning technology, we are moving forward rapidly to bring innovative therapies to market.

We are presently devoting most of our resources to the commercialization or development of our four most advanced drug programs:

  • XERMELO® (telotristat ethyl), which we are marketing for carcinoid syndrome diarrhea;
  • Telotristat ethyl, which we are studying in biliary tract cancer;
  • Zynquista™ (sotagliflozin), which has been approved in the European Union for type 1 diabetes;
  • Sotagliflozin, which we are developing for type 1 and type 2 diabetes;
  • LX2761, which we are developing for diabetes; and
  • LX9211, which we are developing for neuropathic pain.

LXRX - Pipeline Progress

Compound Partner Target Indication Preclinical Phase 1 Phase 2 Phase 3 Registration Marketed
XERMELO® Wholly owned (U.S./ Japan) TPH1 Carcinoid Syndrome diarrhea
XERMELO® Ipsen (ex-U.S./ ex-Japan) TPH1 Carcinoid Syndrome diarrhea
Zynquista™ Wholly owned SGLT1/
Type 1 Diabetes (T1D) EU
EMA approval Apr 26, 2019
Sotagliflozin Wholly owned SGLT1/
Type 1 Diabetes (T1D) US
Sotagliflozin Wholly owned SGLT1/
Type 2 Diabetes (T2D)
Telotristat ethyl Wholly owned (U.S./ Japan) TPH1 Biliary tract cancer (BTC)
LX2761 Wholly owned SGLT1
(GI tract)
LX9211 Wholly owned AAK1 Neuropathic Pain


XERMELO is a prescription pill, used along with somatostatin analog (SSA) therapy, for Carcinoid Syndrome diarrhea in adults who are not adequately controlled by SSA therapy.

Important Safety Information

  • XERMELO may cause constipation which can be serious. You should stop taking XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops. Talk to your doctor if you have these symptoms.
  • The most common side effects of XERMELO include nausea, headache, increase in hepatic enzymes, depression, flatulence, decreased appetite, swelling of your hands and feet, and fever.
  • Talk to your doctor about all medicines you are taking as some may interact with XERMELO.

For more information about XERMELO, see Full Prescribing Information.